Articles On CannPal Animal Therapeutics (ASX:CP1)

Almost two years after buying back majority control of CannPal Animal Therapeutics from the recently delisted AusCann, CEO and founder Layton Mills has struck a major partnership agreement that could see the company’s medicinal cannabis pro...

Just two years after medicinal cannabis company AusCann (ASX: AC8) acquired CannPal Animal Therapeutics in a scrip-based deal worth $17.5 million at the time, the group has today announced it will be divesting 52 per cent of its stake in th...

The Australian medicinal cannabis market has seen strong growth in 2021, with revenue from product sales estimated at $230 million. And medical cannabis prescriptions are at an all-time high. The TGA said 13,666 Australian patients were app...

Australian medicinal cannabis company AusCann (ASX: AC8) today announced it is preparing a trial of its proprietary cannabinoid-based formulations in people with spinal cord injury (SCI). The company, which acquired CannPal Animal Therapeu...

Cannabis stocks have welcomed the change in ownership of Pershing Australia from Bank of New York Mellon (BNYM) to Finclear Pty Ltd which – effective immediately – will allow the trading of cannabis securities on the ASX. In late 2019, BNYM...

The ASX saw the best IPO debut of the year to date in manganese explorer Firebird Metals (ASX:FRB), which rose 198 per cent on debut. This beat the previous 2021 record held by WA telco Pentanet (ASX:5GG), which finished its first day in la...

CannPal Animal Therapeutics (ASX: CP1) shareholders voted overwhelmingly in favour of allowing cannabis company AusCann (ASX: AC8) to acquire the company for $17.5 million at a meeting yesterday. If the Supreme Court of Western Australia...

Summary With COVID-19 giving the opportunity to develop products, enhance services and conduct R&D, healthcare sector will be vigilantly gauged. Early spotting of a winning penny stock can offer considerable rewards to patient and...

Australia has one of the highest rates of household pet ownership in the world. The RSPCA estimates 61 per cent of Australian households own pets and all up there are over 29 million pets across the country. The most common domesticated an...

Layton Mills' company CannPal Animal Therapeutics (ASX: CP1) may be the target in a scrip-based acquisition from medicinal cannabis industry peer AusCann Group (ASX: AC8), but that doesn't mean he'll be cashing in and walking out the door w...

It’s been another positive day on the ASX in the wake of Democrats gaining control of the US Senate – but small caps have once again underperformed their larger peers. The Small Ordinaries index of 200 small-cap companies closed Friday up 1...

  Summary AusCann Group to change its CEO after completing the acquisition of the animal health company, CannPal Animal Therapeutics Limited. Nick Woolf, CEO AusCann, agreed to tender his resignation but decided to work as Interim CEO t...

The AusCann Group Holdings Ltd (ASX: AC8) share price is on the move on Friday after the release of an announcement. In morning trade the medicinal cannabis company’s shares are up 14% to 24 cents. What did AusCann announce? This morning A...

The CannPal Animal Therapeutics Ltd (ASX: CP1) share price is shooting higher today, rising 20% to 15 cents per share. The CannPal share price closed at 12 cents a share last Friday after the company was placed in a trading halt. CannPal o...

The Auscann Group Holdings Ltd (ASX: AC8) and Cannpal Animal Therapeutics Ltd (ASX: CP1) share prices will be on watch tomorrow. (Assuming, of course, that the ASX system has returned to functionality by then!) Both companies entered a tra...

Australian Pharmaceutical company AusCann Group Holdings Ltd (ASX:AC8) has entered a scheme implementation deed with CannPal Animal Therapeutics Limited to acquire 100% issued share capital of CannPal. Under the terms of the Scheme Impleme...

Special Report: CannPal Animal Therapeutics (ASX:CP1) has entered into a scheme implementation deed with AusCann Group Holdings (ASX:AC8), agreeing to ... Read More The post A ‘game-changing’ cannabis merger: AusCann buys their way into the...

Two major ASX-listed medicinal cannabis companies could soon be under one roof after the board of CannPal Animal Therapeutics (ASX: CP1) agreed to a scrip-based buyout from AusCann Group (ASX: AC8). If the deal goes ahead CannPal investor...

Special Report: Animal Health company CannPal Animal Therapeutics is moving forward with bringing its hemp-based canine atopic dermatitis therapy to ... Read More The post CannPal Animal Therapeutics signs agreement to register doggie drug...

ASX cannabis stocks are continuing their victory lap following yesterday’s decision by the TGA to re-classify low-dose cannabidiol (CBD) products. The TGA has made an interim decision to down schedule CBD products, including oil and pills,...

StockTalk is a Stockhead video series featuring a roundtable of experts discussing a new investment topic each week. In this edition, host Dr Nigel Finch discusses the ‘hidden gem’ animal health market. Populating the expert panel this week...

A quick wrap of the ASX’s key winners and losers on Thursday, August 6. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 851 stocks rose, 506 declined and...

Nearly two years of pain for Factor Therapeutics (ASX:FTT) shareholders could be over soon with the company signing a term sheet to negotiate a potential acquisition. In 2018, Factor was trying to commercialise a wound-dressing drug, which...

CannPal Animal Therapeutics (ASX: CP1) is a step closer to commercialisation after its oral hemp-based CBD nutraceutical DermaCann was shown to “substantially” reduce atopic dermatitis in dogs during a recent clinical study. The company has...

Pet pharmaceuticals company CannPal (ASX: CP1) is in advanced discussions with commercialisation partners for its oral nutraceutical DermaCann, which has demonstrated reduced skin inflammation for dogs with atopic dermatitis. The company...

Special Report: Animal health company CannPal has released data from a study into its hemp-derived cannabidiol (CBD) nutraceutical for skin and immune support in dogs, and the results will open markets around the world for the ambitious bio...

A quick wrap of the ASX’s key winners and losers on Tuesday, July 7. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 571 stocks rose, 750 declined and 786...

North American pot stocks are roaring back from lows in March but the same cannot be said for their antipodean counterparts, many of which continue to wallow. The New Cannabis Ventures Global Cannabis Stock Index soared 26 per cent last wee...

Special Report: Cannabis products for pets is big business but just two ASX-listed companies are paying it much attention – and only one is making money in the sector. For some pet owners their beloved kitty or canine is their baby, and th...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

After a morning scare, the ASX managed to pare back its losses to close slightly green. While today’s gains are certainly muted, it’s as good as investors could hope for after a grim night on Wall Street set global markets up for a toug...

CannPal Animal Therapeutics (CP1) has been granted global rights to commercialise its MicroMAX microencapsulation technology The licence was granted by the Commonwealth Scientific and Industrial Research Organisation (CSIRO) MicroMAX prote...

Commercialisation is on the cards for pet pharmaceuticals company CannPal (ASX: CP1) after the company signed a deal with the Commonwealth Scientific and Industrial Research Organisation (CSIRO). The agreement has seen the CSIRO grant Can...

Following an 18 month review, CannPal (ASX: CP1) has secured exclusive rights to commercialise the Commonwealth Scientific and Industrial Research Organisation’s (CSIRO) patented MicroMAX platform for use in its hemp and cannabis-based anim...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Marijuana is the hottest herb on the planet right now, but while investing in medical cannabis stocks could make you a fortune, it could also risk the house. After a flurry of activity on the ASX in 2017 as the sector kicked off following l...

Pot stock THC Global (ASX:THC) is in business at Southport, the largest medicinal cannabis production hub in the southern hemisphere. The company announced the release of its completed Canndeo line of cannabis medicines, cultivated using ma...

Who needs human companionship when we have pets? They’re loyal, always happy to see you and won’t divorce you and take half your stuff. According to the RSPCA, Australia is home to 24 million domestic animals. Dogs were present in 38 per ce...

Cannabis Shares Valuing a cannabis company is becoming an increasingly difficult task. Lately, the cannabis shares have been taking a beat in the domestic markets, falling from their respective all-time highs. The table below provides you w...

All eyes were on the nation’s capital yesterday, as the ACT became the first Australian state or territory to legalise marijuana possession. The new laws are expected to come into effect on January 31, 2020. The bill, proposed by Labor back...

It is now accepted that cannabis is not just for those wanting to get high; it has potential to address medical problems. But there’s been little attention on one specific market segment: pets. What is most popular is CBD, which is a non-i...

Wth the legalisation of medical cannabis in many countries like Canada, the global medical cannabis industry has boomed quite a bit in recent times. Let’s take a quick look at 20 cannabis companies trading on ASX. Cann Group Limited (ASX:...